GH Guardant Health, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Precision oncology company providing liquid biopsy and blood-based tests for cancer detection, treatment selection, and monitoring across all disease stages
• • New emphasis: Expanded Guardant Reveal test for late-stage therapy response monitoring; Shield test granted FDA Breakthrough Device status for multi-cancer detection
• • Strategic shift: Migration of key tests (Guardant360 Liquid, Reveal) to proprietary Smart Platform leveraging multiomic data and AI for enhanced sensitivity and insights
• • Quantitative highlight: Global expansion includes launch of Guardant360 CDx testing at Policlinico Gemelli in Italy (Dec 2025) and reimbursement approval in Japan (July 2023)
• • Noteworthy fact: Shield blood test is first FDA-approved and Medicare-covered primary colorectal cancer screening blood test, now included in NCCN screening guidelines

Risk Factors

• • Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing
• • Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results
• • Limited laboratory capacity and unautomated processes constrain scaling; facility expansion and equipment procurement delays possible
• • Competitor Roche-owned Foundation Medicine, Exact Sciences, and others increasing M&A and development efforts in liquid biopsy and genomic profiling
• • Revenue concentration: Top 5 biopharmaceutical customers contributed 11% of total revenue in 2025, risking material financial impact if lost

Management Discussion & Analysis

• • Revenue $982.0M in 2025 vs $739.0M in 2024, up $243M or 32.9% YoY
• • Net loss improved to $416.3M in 2025 from $436.4M in 2024, margin not explicitly stated
• • Best segment: Oncology tests for clinical customers, supported by expanded Medicare coverage and FDA approvals
• • Worst segment: Not explicitly stated; overall net losses indicate ongoing high operating expenses
• • Cash & equivalents $1.3B as of Dec 31, 2025; capital allocation details on buybacks/dividends not disclosed
• • Increased R&D spending on new product innovation and large clinical studies (e.g., Shield post-approval SOLAR study)
• • Management outlook highlights focus on international expansion, payer coverage improvements, and reimbursement risks

What are the latest GH SEC filings in 2026?

Guardant Health, Inc. (GH) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did GH file its most recent 10-K annual report?

Guardant Health, Inc. (GH) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view GH 10-Q quarterly reports?

Guardant Health, Inc. (GH)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every GH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has GH filed recently?

Guardant Health, Inc. (GH)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find GH insider trading activity (Form 4)?

SignalX aggregates every GH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does GH file with the SEC?

Guardant Health, Inc. (GH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GH filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Guardant Health, Inc. (GH).

What is GH's SEC CIK number?

Guardant Health, Inc. (GH)'s SEC CIK (Central Index Key) number is 1576280. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1576280 to look up all GH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find GH return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Guardant Health, Inc. (GH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.